In soft tissue sarcoma, pazopanib improves PFS without affecting HRQoL
the ONA take:
Pazopanib improved progression-free survival but did not impact health-related quality of life in patients with soft tissue sarcoma who experienced disease progression during or after prior chemotherapy, according to a new study published in the journal Cancer.
The global, double-blind, phase III PALETTE trial found that pazopanib 800 mg as second-line or later treatment improved median progression-free survival by 3 months compared with placebo in patients with advanced soft tissue sarcoma. Researchers also found that the most common adverse events associated with pazopanib treatment were diarrhea, fatigue, hypertension, nausea, and weight loss.
Researchers also conducted an exploratory analysis to evaluate the impact of pazopanib treatment on health-related quality of life. Patients were assessed using the 30-item core EORTC Quality-of-Life Questionnaire at baseline and at 4, 8, and 12 weeks of treatment.
Results showed that there was no statistically significant different in global health status between pazopanib and placebo; however, those receiving pazopanib reported significantly worse scores for diarrhea, fatigue, loss of appetite, and nausea/vomiting than those who received placebo. Researchers found that health-related quality of life score tended to decrease over time in both treatment groups.
Pazopanib (Votrient) was initially approved by the U.S. Food and Drug Administration in 2009 for the treatment of patients with advanced renal cell carcinoma.
Pazopanib improved PFS but did not impact HRQoL in patients with soft tissue sarcoma who experienced disease progression during or after prior chemo.
Sign Up for Free e-newsletters
- Fluorouracil Associated With Reduced Surgery for Squamous Cell Carcinoma
- Incidence of Post-traumatic Stress Disorder High Among Patients With Cancer
- Long-Term Night Shift Work Associated With Cancer Risk in Women
- Distress, Neuroticism Predict Long-term Emotional Distress After Cancer Diagnosis
- FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC
- Bacteria in Probiotics Carry Potential Risks for Immunocompromised Patients
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Patient Satisfaction Ratings Can Be Negatively Impacted by Nurse Staffing Ratio
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Comparison of Survival Outcomes Between Radical Hysterectomy and Definitive Radiochemotherapy in Stage IB1 and IIA1 Cervical Cancer
- Fosfomycin Effective Alternate for Febrile Neutropenia Prophylaxis
- Adherence to Skin Cancer Screening Guidelines Beneficial in Management SCC in SOTRs
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|